CHGCY Chugai Pharmaceutical (ADR)
- 15.850
- +0.010+0.06%
Chugai Pharmaceutical (ADR) News
Chugai Pharmaceutical Allots 594 Million Yen Worth of Shares as Restricted Stock Compensation
Chugai Pharmaceutical (TYO:4519) has completed the disposal of 593.9 million yen worth of treasury shares as restricted stock compensation to some directors, top management, and employees, according t
Nikkei Average Contribution Ranking (advance closing) ~ The Nikkei Average fell for the first time in 3 days, and Fast Rite was pushed down by about 49 yen per brand
The number of gains and falls of the Nikkei Average constituent stocks at the time of closing 1 day ago was 44 stocks with price increases, 181 stocks with price drops, and 0 stocks unchanged. The Nikkei Average fell for the first time in 3 days. The forward market transaction was closed at 38189.54 yen (estimated turnover of 880 million shares), which was 216.12 yen lower (-0.56%) compared to the previous day. The US stock market fell on April 30. The Dow average depreciated by $570.17 (-1.49%) at $37815.92, and the Nasdaq depreciated by 325.26 points (-2.04%)
Nikkei average contribution ranking (advance closing) ~ The Nikkei Average continues to rise drastically, and TOEREC boosts 1 brand by about 90 yen
The number of gains and falls of the Nikkei average constituent stocks at the time of closing 30 days ago was 188 stocks with price increases, 37 stocks with price drops, and 0 stocks unchanged. The Nikkei Average continued to rise drastically. The front-end transaction was closed at 38459.01 yen (estimated turnover of 980 million shares), which was 524.25 yen higher (+ 1.38%) compared to the previous business day. The US stock market continues to grow. The Dow average rose by $146.43 (+ 0.38%) to $38386.09, and the Nasdaq rose 55.19 points (+ 0.35%) to 15983.09
Nikkei average contribution ranking (advance closing) ~ The Nikkei Average rebounded, and TOEREC boosted by about 61 yen with 1 brand
The number of gains and falls of the Nikkei Average constituent stocks as of closing 26 days ago was 121 stocks with a price increase and 101 stocks with a price drop of 3 stocks unchanged. The Nikkei Average rebounded. The front-end transaction was closed at 37780.35 yen (estimated volume of 740 million shares), which was 151.87 yen higher (+0.40%) compared to the previous day. The US stock market declined on the 25th. The Dow average depreciated by 375.12 dollars (-0.98%) at 38085.80 dollars, and the NASDAQ depreciated 100.99 points (-0.64%) at 15611.
Brands that moved the day before part 2 Sakura Gome, Smart Value, Chugai Pharmaceutical, etc.
<コード>Stock name closing price on the 25th ⇒ compared to the previous day Pana HD ＜6752＞ 1325 -68 earnings forecasts were revised downward centered on transient factors. CyberAgent ＜4751＞ 976.5 -58.5 The first half of the year's positive financial results were also exhausted, and the feeling prevailed. GURUNAVI ＜2440＞ broke through the 302-1325 line and had an advantage in closeout sales. Chugai Pharmaceutical＜4519＞ 4860-291 saw a drastic decrease in sales for the first quarter. Hino Motors ＜7205＞ 462.6 -29.325 financial results
Earnings Call Summary | CHUGAI PHARMACEUTICAL CO(CHGCF.US) Q1 2024 Earnings Conference
The following is a summary of the Chugai Pharmaceutical Co., Ltd. (CHGCF) Q1 2024 Earnings Call Transcript:Financial Performance:Chugai Pharmaceutical's Q1 2024 revenue reported a decrease of 24.1% ye
Meta Water, Canon, Avionics, etc.
＜4519＞ Chugai Pharmaceutical 4860-291 continued to decline drastically. Financial results for the first quarter were announced the day before. Core operating income was 102.1 billion yen, down 3.1% from the same period last year, but market consensus has improved due to a cost ratio decline higher than expected. However, sales revenue declined drastically, with a 24.1% decrease from the same period. In addition to the decline in sales due to the completion of deliveries to the Rona Grove government, Babysmo, Alesensa, etc. also fell short of expectations, and overseas shipments of Actemra also seem to have declined due to the effects of biosimilars. sluggish
Movements to avoid risk due to concerns about the performance of Japanese and American companies
The Nikkei Average fell sharply. The transaction closed at 37628.48 yen (estimated turnover of 1.59 billion shares), which depreciated by 831.60 yen. Profit-taking sales took precedence from the reaction that had risen by over 900 yen the day before. Also, the fact that US Meta Platforms, which showed a sluggish earnings forecast, was plummeting overtime worsened investor sentiment, and performance unease of domestic high-tech companies was also alarmed, and the Nikkei Average remained soft throughout the day. The fact that US stock index futures continue to be soft also strengthens the buy-off attitude
Chugai Pharmaceutical --- drastic decline, with a drastic decline in sales in the first quarter
Chugai Pharmaceutical ＜4519＞ continues to decline drastically. Financial results for the first quarter were announced the day before. Core operating income was 102.1 billion yen, down 3.1% from the same period last year, but market consensus has improved due to a cost ratio decline higher than expected. However, sales revenue declined drastically, with a 24.1% decrease from the same period. In addition to the decline in sales due to the completion of deliveries to the Rona Grove government, Babysmo, Alesensa, etc. also fell short of expectations, and overseas shipments of Actemra also seem to have declined due to the effects of biosimilars. Negative low headlines
Front market [stocks that have moved, stocks that have been created]
*Japan Aviation Electronics Industry＜6807＞ 2548 +217 The profit forecast for the current fiscal year exceeds market expectations. *Ordinary income forecasts were revised upward due to large vacuum ＜6962＞ 827 +44 exchange margin recording, etc. *Are Capcom ＜9697＞ 2636 +73.5 evoJapan upcoming events also expected. *Is it a supply-demand factor, such as buybacks in the high price range of NIPPATS ＜5991＞ 1584 +44? *Eisai ＜4523＞ No. 6244 +155 Alzheimer's drug “Rekenbi”
Nikkei Average Contribution Ranking (advance closing) ~ The Nikkei Average fell drastically for the first time in 4 days, and Fast Rite was pushed down by about 126 yen per brand
The number of gains and falls of the Nikkei Average constituent stocks as of closing 25 days ago was 32 stocks with price increases, 193 stocks with price drops, and 0 stocks unchanged. The Nikkei Average fell sharply. The forward transaction was closed at 37818.11 yen (estimated turnover of 790 million shares), 641.97 yen lower (-1.67%) compared to the previous day. The US stock market was mixed on the 24th. The Dow average depreciated by 42.77 dollars (-0.11%) to 38460.92 dollars, and the Nasdaq rose 16.11 points (+ 0.10%) to 15712
Chugai Pharmaceutical --- From redividing the partition to aiming for a push
While adjustments continued, peaking at 6697 yen set on 3/11, it was sold up to 4896 yen on 4/19. After that, the 200-day line showed a rebound in the form of functioning as a support line, and the 25th line (around 5454 yen) came into firing range. However, today we are breaking the 200-day line ahead of sales. If there seems to be reluctance to decline around the 200-day line, it will probably be time to start aiming for a push after rearranging the partition.
Kinden, Cosmos Pharmaceuticals, etc. (added) Rating
Downgrading-Bearish Code | Stock Name | Securities Company | Conventional | After Change |------|---------|---------|---------|＜8515＞|AIFUL | Mizuho | “Buy” | “Neutral” | Target Stock Price Change Code | Stock Name | Securities Company | Traditional | After Change |------|-|----
The Nikkei Average started at 394 yen depreciation, and FANUC, Chugai Pharmaceutical, etc. fell
[Nikkei Stock Average, TOPIX (table)] Nikkei Average; 38065.91; -394.17 TOPIX; 2692.26; -18.47 [Close Overview] The Nikkei Average on the 25th fell 394.17 yen to 38065.91 yen for the first time in 4 days and began trading. The US stock market the day before, on the 24th, was mixed. The Dow average closed at 38460.92 dollars, down 42.77 dollars, and the Nasdaq closed at 15712.75, which was 16.11 points higher. Semiconductor manufacturer Texas ·
Panasonic revises 24/3 downward operating profit of 360 billion yen ← 400 billion yen
Panasonic (6752) announced revisions to its earnings forecast for the fiscal year ending 2024/3. Sales were revised upward from 8.4 trillion yen to 8.5 trillion yen due to the fact that the exchange rate of yen remained weaker than expected, etc. Meanwhile, operating income has been revised downward from 400 billion yen to 360 billion yen. There were provisions relating to handling defective manufacturing products in the past in Energy's automotive battery business, and goodwill impairment losses related to part of the automotive business as other profits and losses (approx.
Check out the disclosed information for [Tomorrow's Good and Bad Materials]! (Announced on 4/24)
[Good material] ---- ---- ■Fujiya [Tokyo Stock Exchange P] January-March (1Q) regular accounts landed with an 11% increase in profit. ■Cube System [Tokyo Stock Exchange P] dividend for the first fiscal year was increased by 5 yen and revised. In addition, a medium-term management plan was formulated. We aim for operating profit of 2.41 billion yen for the fiscal year ending 27/3 (1.62 billion yen for the fiscal year ending 24/3 plan). ■Transgenic [Tokyo Stock Exchange G] revised its previous fiscal year accounts upward to a complete surplus. ■Natori [Tokyo Stock Exchange P]
Chugai Pharmaceutical 1Q Net Y74.40B Vs Net Y73.50B
Chugai Pharmaceutical Co. Ltd. (4519.TO) Tokyo 1st Quarter Ended March 31 GROUP 2024 2023 Revenue Y236.95 bln Y312.24 bln Operating Profit
The risk appetite mood strengthens by projecting high US stocks
The Nikkei Average continued to rise drastically. The transaction was closed by recovering to the 38,000 yen level for the first time in 4 business days since the 18th on a closing price basis of 38460.08 yen (estimated turnover of 1.74 billion shares), which rose 907.92 yen. Prices rose mainly on high-tech related stocks in response to a trend where growth stocks, which are considered sensitive to interest rate trends, were bought against the backdrop of a pause in long-term interest rate increases in the US market the day before. If the Nikkei Average recovered to 38,000 yen soon after getting close, it continued to move in the high price range even after that, and today's high
The Nikkei Average rose by 811 yen, and there is interest in the financial results of major domestic and foreign companies
The Nikkei Average is 811 yen higher (as of 14:40). In terms of the Nikkei average contribution, East Elec ＜8035＞, Fast Rite ＜9983＞, Advantest ＜6857＞, etc. are top positive contributors, while KDDI ＜9433＞, Astellas Pharma ＜4503＞, Nidec ＜6594＞, etc. rank high for negative contributions. In the sector, precision equipment, electrical equipment, transportation equipment, wholesale trade, machinery have the highest price increase rate, pulp/paper, electric/gas, land transportation, and real estate
Nikkei Average Contribution Ranking (advance closing) ~ The Nikkei Average continues to rise, and Fast Rite boosts by about 52 yen per brand
The number of gains and falls of the Nikkei average constituent stocks as of closing 23 days ago was 125 stocks with price increases, 94 stocks with price drops, and 6 stocks unchanged. The Nikkei Average continued to rise slightly. The front-end transaction was closed at 37538.06 yen (estimated turnover of 740 million shares), which was 99.45 yen higher (+0.27%) compared to the previous day. The US market rose on the 22nd. The Dow average rose by $253.58 (+0.67%) to $38239.98, and the Nasdaq rose 169.29 points (+1.11%) to 15451.30
Analysis
Price Target
No Data
